Galectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Galectin Therapeutics

14/08/2026 14:52

Galectin Therapeutics Inc GALT.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents.  The lone analyst forecast for the quarter was for a loss of 9 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Galectin Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $9.18 million.
Galectin Therapeutics Inc shares had fallen by 23.9% this quarter and lost 15.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Galectin Therapeutics Inc is $11.00, about 67.9% above its last closing price of $3.53
This summary was machine generated from LSEG data August 14 at 01:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.09
-0.14
Missed
Mar. 31 2026 
-0.06
-0.08
Missed
Dec. 31 2025 
-0.10
-0.08
Beat
Sep. 30 2025 
-0.11
-0.13
Missed